# SOLARA: HCP commentary report

> 71 verified statements (6 from clinicians verified by NPI or staff page) from 23 commentary sources · 7 findings · updated Oct 29, 2026

## Report

- Trial: A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
- NCT ID: NCT06706076
- Registry: https://clinicaltrials.gov/study/NCT06706076
- Sponsor: BlossomHill Therapeutics
- Phase: Phase 1/Phase 2
- Status: Recruiting
- Drugs tested: BH-30643; BH-30643 plus carboplatin plus pemetrexed
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 392661c28eda3bb8f5e8c0cfd7b6ab8433811c1ba9e95e7d09d69147e57d0b50

## Counts

- HCP commentary sources screened: 88
- Sources cited by verified statements: 23
- Verified statements: 71
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 6
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 7
- Voices cited: 6
- Cited voices identity-verified: 4
- Organisational or shared accounts (not counted as people): 12

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on SOLARA in the sources reviewed for this edition leads to one open question: What durability, hepatic-event timing and subgroup-specific comparative evidence would make the proposed roles and monitoring burden clinically persuasive? Its leading findings: (1) acceptable liver monitoring is not the same as resolved hepatic risk. (2) early response optimism remains qualified by durability, selection and the limits of an oral-option narrative. (3) proposed positioning is selective, not blanket replacement of osimertinib. 4 more findings follow. 88 sources screened, 23 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What durability, hepatic-event timing and subgroup-specific comparative evidence would make the proposed roles and monitoring burden clinically persuasive?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Acceptable liver monitoring is not the same as resolved hepatic risk
- F2. Early response optimism remains qualified by durability, selection and the limits of an oral-option narrative
- F3. Proposed positioning is selective, not blanket replacement of osimertinib
- F4. Mutation breadth is valued because resistance can be heterogeneous
- F5. CNS exposure versus comparative intracranial benefit
- F6. Referral enthusiasm includes slot constraints and a patient-support role
- F7. Development optimism should remain separate from regulatory certainty

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 14 | 8 | 5 | 5 | recorded | 2 |
| F2 | 10 | 9 | 7 | 6 | recorded | 3 |
| F3 | 8 | 2 | 2 | 2 | recorded | 2 |
| F4 | 11 | 9 | 7 | 5 | recorded | 3 |
| F5 | 6 | 4 | 4 | 3 | none recorded | 2 |
| F6 | 6 | 3 | 3 | 2 | none recorded | 2 |
| F7 | 10 | 9 | 6 | 3 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 9 | 2 | 0 | 1 | 2 | 15 | 0 | 4 posts and articles, 1 podcast or video | yes |
| F2 | 7 | 0 | 0 | 0 | 3 | 11 | 0 | 6 posts and articles, 1 podcast or video | yes |
| F3 | 7 | 0 | 0 | 0 | 1 | 8 | 0 | 2 posts and articles | yes |
| F4 | 7 | 1 | 0 | 2 | 1 | 13 | 0 | 5 posts and articles, 2 podcasts and video | yes |
| F5 | 6 | 0 | 0 | 0 | 0 | 6 | 0 | 3 posts and articles, 1 podcast or video | yes |
| F6 | 5 | 1 | 0 | 0 | 0 | 6 | 0 | 3 posts and articles | yes |
| F7 | 5 | 1 | 0 | 0 | 4 | 12 | 3 | 5 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation): no finding draws on it directly
- Primary endpoint: Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization): no finding draws on it directly
- Primary endpoint: Objective Response Rate (ORR) (Phase 2): F1 (1 shared claims), F2 (7 shared claims), F4 (1 shared claims), F7 (1 shared claims)
- Secondary endpoints: F1 (2 shared claims), F2 (2 shared claims), F3 (1 shared claims), F5 (3 shared claims)
- Population and setting: F2 (3 shared claims), F3 (2 shared claims), F4 (3 shared claims), F6 (3 shared claims)
- The comparison: F3 (1 shared claims), F7 (1 shared claims)
- Safety and tolerability: F1 (14 shared claims), F2 (4 shared claims), F3 (1 shared claims), F7 (1 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (2 shared claims), F3 (1 shared claims), F7 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 71 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 23 | Counts free |
| Speaker attribution for cited voices | 6 | Paid |

## Trial aspects

11 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation) | no commentary found | 0 | 0 |
| Primary endpoint: Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization) | no commentary found | 0 | 0 |
| Primary endpoint: Objective Response Rate (ORR) (Phase 2) | discussed | 10 | 8 |
| Secondary endpoints | discussed | 7 | 6 |
| Population and setting | discussed | 14 | 9 |
| The comparison | discussed | 1 | 1 |
| Safety and tolerability | discussed | 19 | 9 |
| Design and conduct | discussed | 8 | 5 |
| Resistance coverage, mechanistic rationale and biomarker interpretation | discussed | 12 | 8 |
| Positioning against osimertinib and alternative regimens | discussed | 13 | 4 |
| CNS exposure and potential intracranial benefit | discussed | 5 | 6 |
| Trial access, patient support and unanswered questions | discussed | 6 | 3 |
| Durability, evolving datasets and regulatory-development expectations | discussed | 12 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 80 | 19 |
| Bluesky threads | 4 | 1 |
| LinkedIn posts | 1 | 1 |
| Podcasts | 1 | 1 |
| X videos | 1 | 1 |
| YouTube | 1 | 0 |

- Screened window: 2025-01-22 to 2026-10-25
- Cited window: 2025-10-24 to 2026-10-08
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
- Registry: NCT06706076 (https://clinicaltrials.gov/study/NCT06706076)
- Study IDs: BH-30643-01
- Sponsor: BlossomHill Therapeutics
- Design: Phase 1/Phase 2 · interventional, non randomized, single group, phase1, phase2
- Status: Recruiting
- Enrollment: 675 (estimated)
- Start: 2025-01-09 (actual)
- Primary completion: 2029-01-31 (estimated)
- Primary endpoint: Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation) (Within the first 21 days of the first dose of BH-30643.)
- Primary endpoint: Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization) (Within 21 days of last participant dosed during Dose Expansion/Optimization.)
- Primary endpoint: Objective Response Rate (ORR) (Phase 2) (Approximately 3 years after the first participant dosed.)
- Intervention: BH-30643 (drug)
- Intervention: BH-30643 combo therapy with Carboplatin/Pemetrexed (drug)
- Intervention: BH-30643 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 2 matching sources (2 X threads) could not be read and are not included.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 51 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- Thirty-four potentially relevant discussions that did not name the trial were not read, two sources could not be read, and multiple passages were not fully assessed. Absence of commentary in a topic should therefore not be interpreted as absence of clinician concern.
- The material mixes clinician-attributed posts, sponsor statements, organizations, investment-oriented accounts and unidentified spoken commentary. Repeated announcements and reposts are not additional independently expressed clinical views.
- Clinical roles are not established for several named authors. Professional identifiers and affiliations provide background only; they do not establish who spoke an unidentified passage or increase the weight of an opinion.
- No full results publication or protocol document was available in the sources reviewed. No exact product label was identified for BH-30643 alone or with carboplatin/pemetrexed, so commentary cannot substitute for detailed methods, adjudicated safety information or regulatory documentation.
- Response estimates and safety percentages refer to different data summaries, populations, doses and event categories. Their differences do not establish a temporal trend, contradiction or change of mind.
- Several BH-30643 discussions never name SOLARA. They are included for their relevance to the same clinical decision and are identified by their stated setting, rather than treated as additional SOLARA analyses.
- The episode gives inconsistent FDA-meeting dates. Neither date is selected as confirmed, and development plans, accelerated-approval aims and analyst success assumptions remain prospective.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition, corrected 2026-10-29
  - Correction 2026-10-29: The page names the trial's tested drugs (BH-30643; BH-30643 plus carboplatin plus pemetrexed).

Last checked for new commentary 2026-10-29. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (71 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (4 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/solara-nct06706076
- Agents: POST https://www.erudio.com/api/orders with {"report": "solara-nct06706076", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=solara-06706076

## Cite

Erudio Health. SOLARA (NCT06706076): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/solara-nct06706076

## Machine access

- JSON: https://www.erudio.com/reports/solara-nct06706076.json
- Markdown: https://www.erudio.com/reports/solara-nct06706076.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "solara-06706076"}`